The Regnase proteins, encoded by the ZC3H12 gene family, are RNA-binding endoribonucleases, meaning they cut messenger RNA molecules directly rather than merely tagging them for degradation. Each member carries a conserved CCCH zinc-finger domain paired with a PilT N-terminus-like nuclease domain, a structural combination that coordinates the recognition and cleavage of target transcripts. The founding member, Regnase-1, also known as MCPIP1 or ZC3H12A, was first identified in 2009 as an RNase essential for controlling immune responses by regulating mRNA decay. Its targets include some of the most potent inflammatory messengers in the body: transcripts encoding interleukin-6, interleukin-1 beta, interleukin-12 and tumor necrosis factor. By trimming the lifespan of these mRNAs, Regnase-1 acts as a built-in brake on inflammation.

What makes the brake remarkable is that it is deliberately released when the immune system needs to fire. Following stimulation of Toll-like receptors or interleukin-1 receptors, the I-kappa-B kinase complex phosphorylates Regnase-1, triggering its degradation and allowing inflammatory mRNA to accumulate so that effector programs can begin. In helper T cells, the paracaspase MALT1 cleaves Regnase-1 after T-cell receptor engagement, a mechanism that permits rapid T-cell activation. In group 2 innate lymphoid cells, degradation of Regnase-1 is crucial for responses to interleukin-33 and interleukin-25. These are not accidents of biology; they are controlled, transient losses of enzymatic activity that give immune cells a window in which to respond. The trouble starts, the review argues, when that window fails to close and activity is not restored, prolonging inflammation beyond its useful purpose.

The review is emphatic that the four family members cannot be treated as interchangeable. Regnase-2 appears to serve a homeostatic function that restrains neuroinflammation, while Regnase-3, expressed in myeloid cells, is required for immune homeostasis and regulation of the type I interferon pathway. Recent work also points to crosstalk between Regnase-1 and Regnase-3 in shaping mast cell survival and cytokine expression. Each member differs in cellular distribution, in its repertoire of RNA substrates, and in its contribution across disease stages. Regnase-1 and Regnase-3, for instance, jointly control the expression of Nfkbiz and thereby influence the balance between lymphoid and myeloid lineage commitment. This heterogeneity means that a drug targeting one member may produce entirely different effects depending on which cells express it and when.

Nowhere is that heterogeneity clearer than in the T-cell compartment. Transgenic expression of a catalytically active mutant Regnase-1 in T cells disturbs T-cell development and function, and genetically modulating the protein reveals a critical role in regulatory T cell homeostasis in vivo. In other words, persistently high Regnase-1 activity in selected T-cell populations can itself destabilize immune balance, just as persistently low activity can fuel autoimmunity. A Regnase-1 D141N mutation has been shown to induce CD4-positive T cell-mediated lung granuloma formation through upregulation of the kinase Pim2. Regnase-1 also suppresses the formation of TCF-1-positive precursor exhausted T cells, thereby limiting CAR-T cell responses against acute lymphoblastic leukemia, a finding that has pushed the protein into the spotlight of cancer immunotherapy as well as autoimmunity research.

Beyond T cells, the review catalogs Regnase-1’s influence across an extraordinary range of tissues and disease models. In rheumatoid arthritis, the enzyme post-transcriptionally regulates interleukin-6 production in fibroblast-like synoviocytes, and the RNA-binding protein Roquin-1 cooperates with Regnase-1 to suppress fibroblast growth factor 2 and NF-kappa-B signaling, restraining disease progression. Disrupting the Roquin-1 and Regnase-1 interaction, conversely, induces autoimmunity while enhancing antitumor responses, underscoring the double-edged nature of the pathway. In the skin, keratinocyte-specific loss of Regnase-1 impairs skin integrity and abruptly activates the interleukin-23 and T helper 17 axis, while the enzyme restricts interleukin-17A- and interleukin-17C-dependent skin inflammation and maintains immune homeostasis through regulation of chemokine expression. In ankylosing spondylitis, Regnase-1 regulates inflammation in T cells through the TRAF6 adaptor protein.

The enzyme’s reach extends deep into barrier tissues and even into non-immunological pathology. In the lung, Regnase-1 orchestrates interplay between epithelium and the adaptive immune system to protect against pneumonia, and its deficiency restrains Klebsiella pneumoniae infection by dysregulating type I interferon responses. Pulmonary Regnase-1 in alveolar macrophages degrades transcripts encoding interleukin-6 and platelet-derived growth factor, preventing pulmonary arterial hypertension, while profibrotic functions of group 2 innate lymphoid cells are held in check by the same enzyme. In the kidney, macrophage-specific Regnase-1 attenuates ischemia-reperfusion injury by shaping local inflammatory responses and tissue regeneration, and an interleukin-17-driven inflammatory circuit in renal tubular epithelial cells that amplifies antibody-induced glomerulonephritis is constrained by the protein. In the gut, epithelial Regnase-1 inhibits colorectal tumor growth by degrading NFKBIZ mRNA and thereby damping interleukin-17 signaling, and the enzyme supports colon epithelial regeneration through regulation of mTOR and purine metabolism. Even osteoarthritis and Marfan syndrome have been linked to its activity, with upregulated Regnase-1 suppressing catabolic signaling in chondrocytes and Regnase-1 overexpression proposed as a therapeutic approach for Marfan pathology.

Translational efforts are already under way, and the review highlights one of the most inventive strategies to date: antisense oligonucleotides that bind a stem-loop structure in the 3-prime untranslated region of the Regnase-1 mRNA itself. Regnase-1 normally represses its own translation through this autoregulatory element, so blocking the interaction with a stem-loop-targeting oligonucleotide releases the brake on Regnase-1 protein production. In preclinical models, enhancing Regnase-1 expression this way alleviated inflammatory disease, providing proof of concept that the protein’s output can be therapeutically raised without altering the gene itself. Local protein or gene augmentation strategies, including adeno-associated virus serotype 9 delivery, have likewise shown preclinical promise, while other platforms such as lipid nanoparticles and proteolysis-targeting chimeras remain exploratory. The appeal of these approaches is selectivity: rather than globally suppressing cytokines, they restore a natural quality-control mechanism.

The authors are careful, however, to temper enthusiasm with a sober assessment of what remains unknown. Because Regnase-1 activity is beneficial in some cells and harmful in others, and because both transient loss and persistent excess can disturb homeostasis, any successful therapy must be cell selective, reversible, and confined to an appropriate disease window. Achieving that will demand temporally resolved human samples and direct measurements of protein state, RNA binding, and target decay, rather than relying on static snapshots of messenger RNA abundance. Single-cell and spatial transcriptomic studies of lupus nephritis, rheumatoid arthritis synovium and psoriatic skin have begun to map the cellular landscapes in which these enzymes operate, and techniques such as enhanced cross-linking and immunoprecipitation, RNA velocity analysis and simultaneous epitope and transcriptome measurement offer the resolution needed to track Regnase dynamics in real time.

The broader significance of the review lies in its reframing of post-transcriptional regulation as a central pillar of autoimmunity. For years, immunology has focused on transcription factors and signaling cascades, treating mRNA decay as background housekeeping. The Regnase family demonstrates that the lifespan of an inflammatory transcript can be as decisive as the signal that produced it, and that the same enzyme can protect against pneumonia, prevent pulmonary hypertension, restrain skin inflammation and yet, when mis-timed, contribute to granulomatous lung disease or impaired antitumor immunity. As population studies document rising incidence and co-occurrence of autoimmune disorders across tens of millions of individuals, the search for therapies that correct molecular timing rather than blanket suppression has acquired new urgency. Regnase-1, sitting at the junction of RNA chemistry and immune regulation, may prove to be one of the most instructive targets in that search.

Subject of Research: Post-transcriptional regulation of inflammation by the Regnase family of endoribonucleases in autoimmune diseases

Article Title: The regnase family in autoimmune diseases: a regnase-1-centered perspective on cellular heterogeneity

Article References: Li, Y., Liu, Y., Su, Y., Wang, Y., & Wang, X. (2026). The regnase family in autoimmune diseases: a regnase-1-centered perspective on cellular heterogeneity. Molecular Biology Reports, 53(1), Article 1671. https://doi.org/10.1007/s11033-026-12852-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12852-1

Keywords: Regnase-1, autoimmune diseases, mRNA degradation, endoribonucleases, post-transcriptional regulation, immune homeostasis, T cells, interleukin-6, NF-kappa-B, antisense oligonucleotides, Roquin-1, cellular heterogeneity